Chika V. Anekwe, MD, MPH

The treatment of type 2 diabetes (T2D) has traditionally followed a stepwise approach, beginning with metformin and continuing with the addition of other agents to achieve target glycemic control. 

In this ReCAP, Dr Chika Anekwe, of the Massachusetts General Hospital Weight Center in Boston, Massachusetts, discusses categories for antidiabetic therapies, when to combine medications that have differing mechanisms, and the clinical benefits of combination therapy, such as a stronger response in the reduction of hemoglobin A1c as well as loss of body weight. 

She also discusses tirzepatide, a dual therapy combining glucagon-like peptide-1 agonist and glucose-dependent insulinotropic polypeptide (GIP) agonist, which has shown clinically meaningful results for both blood sugar reduction and body weight reduction for patients with T2D. 

--

Chika V. Anekwe, MD, MPH, Obesity Medicine Physician, Massachusetts General Hospital Weight Center, Boston, Massachusetts 

Chika V. Anekwe, MD, MPH, has disclosed no relevant financial relationships. 

The treatment of type 2 diabetes (T2D) has traditionally followed a stepwise approach, beginning with metformin and continuing with the addition of other agents to achieve target glycemic control. 

In this ReCAP, Dr Chika Anekwe, of the Massachusetts General Hospital Weight Center in Boston, Massachusetts, discusses categories for antidiabetic therapies, when to combine medications that have differing mechanisms, and the clinical benefits of combination therapy, such as a stronger response in the reduction of hemoglobin A1c as well as loss of body weight. 

She also discusses tirzepatide, a dual therapy combining glucagon-like peptide-1 agonist and glucose-dependent insulinotropic polypeptide (GIP) agonist, which has shown clinically meaningful results for both blood sugar reduction and body weight reduction for patients with T2D. 

--

Chika V. Anekwe, MD, MPH, Obesity Medicine Physician, Massachusetts General Hospital Weight Center, Boston, Massachusetts 

Chika V. Anekwe, MD, MPH, has disclosed no relevant financial relationships. 

The treatment of type 2 diabetes (T2D) has traditionally followed a stepwise approach, beginning with metformin and continuing with the addition of other agents to achieve target glycemic control. 

In this ReCAP, Dr Chika Anekwe, of the Massachusetts General Hospital Weight Center in Boston, Massachusetts, discusses categories for antidiabetic therapies, when to combine medications that have differing mechanisms, and the clinical benefits of combination therapy, such as a stronger response in the reduction of hemoglobin A1c as well as loss of body weight. 

She also discusses tirzepatide, a dual therapy combining glucagon-like peptide-1 agonist and glucose-dependent insulinotropic polypeptide (GIP) agonist, which has shown clinically meaningful results for both blood sugar reduction and body weight reduction for patients with T2D. 

--

Chika V. Anekwe, MD, MPH, Obesity Medicine Physician, Massachusetts General Hospital Weight Center, Boston, Massachusetts 

Chika V. Anekwe, MD, MPH, has disclosed no relevant financial relationships.